Epstein-Barr virus components linked to the development of multiple sclerosis have been identified

As a neurologist dedicated for many years to the care of patients with multiple sclerosis (MS), my reading of this work is inevitably clinical. More than analyzing its immunological aspects, which will probably be better assessed by experts in that area, I am particularly interested in what it contributes to a better understanding of the disease and whether it can change the way we treat patients.

Since studies conducted on the cohort of US military personnel, we have known that the Epstein-Barr virus (EBV) is one of the environmental factors most strongly associated with the development of MS. This epidemiological association is now difficult to dispute, especially in people who develop infectious mononucleosis after primary infection. However, we still face a significant clinical paradox: more than 95% of the adult population has been infected with EBV, and only a small proportion develop MS. The great challenge remains understanding what differentiates these patients from the rest of the population.

This is an ex vivo mechanistic study, conducted on peripheral blood mononuclear cells, that combines different immunological approaches and validates its main findings in independent cohorts of patients treated with anti-CD20 antibodies, which, in my opinion, lends methodological rigor to its conclusions.

Until now, a significant part of the research had focused on the nuclear antigen EBNA1, a protein expressed during the latency phase of EBV and essential for maintaining the viral genome in infected cells, as one of the main players in the immune response against the virus. This work provides a complementary perspective by demonstrating that a very important part of the CD4+ T lymphocyte response against the virus is directed against structural proteins of the virion itself, especially capsid proteins and virion envelope glycoproteins, produced during the lytic or active replication phase of the virus.

In my opinion, this is the study's main value. I don't believe it represents a paradigm shift, but it does significantly expand our knowledge of the immunology and biology of MS. Rather than replacing the role previously attributed to EBNA1, this work suggests that different phases of the EBV life cycle and various antigens could play complementary roles in maintaining the immune response.

From a clinical perspective, this is probably the most relevant aspect. This study does not currently alter our clinical practice. It does not change how we diagnose, monitor, or treat our patients, nor does it allow us to draw conclusions about disability, progression, brain or spinal cord atrophy, lesion burden, or cognitive impairment—aspects it does not analyze. However, it does change, at least partially, how we understand the interaction between EBV and the immune system in the disease.

Perhaps the most interesting aspect for a clinical neurologist is that this work offers an additional biological explanation for why B-cell targeted therapies have demonstrated such remarkable efficacy in MS. As clinicians, we have been observing for years the extraordinary efficacy of therapies targeting B cells, especially anti-CD20 antibodies. This study does not demonstrate that this is due to EBV control, but it reinforces the hypothesis that the interaction between the viral reservoir in B lymphocytes and the immune response could be an important component of the disease and deserves further investigation.

The main impact of this work is not on immediate clinical practice, but on future research. Rather than telling us how we should treat our patients today, it helps us better understand why they become ill and opens new lines of research for the rational development of future vaccines and antiviral treatments targeting EBV. If these strategies ever demonstrate clinical benefit, they could change how we prevent or treat the disease, but we are still far from that scenario.

As is often the case in translational research, a better understanding of biological mechanisms does not imply an immediate change in clinical practice, but it does constitute the first step toward developing more specific and effective treatments. This, in my opinion, is the main value of this work.

This study shows that in patients with multiple sclerosis (MS), CD4 lymphocytes are activated in response to the Epstein-Barr virus (EBV) in its lytic (infectious) phase, not in the latent phase. Latent EBV is a proven risk factor and even an etiological factor in MS. In this case, the preferential response was against EBV in its lytic phase, which may suggest greater immunological memory against EBV in individuals who later developed MS. Furthermore, current MS drugs decrease this response, suggesting that this could be a mechanism mediating their efficacy.

The article is excellent and of very high quality. The team is highly expert in this area and complements their previous findings. The results are striking because they demonstrate the relevance of immunological memory against this virus in its lytic phase, rather than in its latent phase, which is what was previously known, thus broadening our understanding of the virus's role in MS.

[Regarding potential limitations] Like many clinical studies, it demonstrates an association, but not causality, between EBV lytic infection and the development or activity of MS. However, it provides further evidence.

The article confirms the clear involvement of the Epstein-Barr virus in the pathogenesis of multiple sclerosis. This article reaffirms that the Epstein-Barr virus is a trigger for the disease and that other viruses, such as CMV and VZV, are not. The results obtained in cell-based assays have been validated in cohorts of healthy individuals and those with multiple sclerosis, as well as in treated and untreated patients.

This article is an in-depth analysis of data from the first author, who published work years ago demonstrating the involvement of the Epstein-Barr virus. Demonstrating that it is the antigens on the viral particles that elicit the immune response opens up new therapeutic avenues, such as developing more specific vaccines against the Epstein-Barr virus, seeking more targeted antivirals, and identifying therapies that could cure the disease at an early stage.

The limitations of this study are that it has only examined the peripheral immune response to the virus, rather than the response of the central nervous system, and that the findings have only been demonstrated in saliva. Furthermore, not all possible treatments have been tested, and the response to the Epstein-Barr virus has not been correlated with clinical improvement. The response to treatment with natalizumab is difficult to explain because, in clinical practice, patients receiving this treatment remain relapse-free for many years.